| Identification | Back Directory | [Name]
3(2H)-Pyridazinone, 4-hydroxy-6-[2-[4-(trifluoromethyl)phenyl]ethyl]- | [CAS]
1425511-32-5 | [Synonyms]
TAK-831
Luvadaxistat
Luvadaxistat (Synonyms: TAK-831)
4-Hydroxy-6-{2-[4-(trifluoromethyl)phenyl]ethyl}pyridazin-3(2H)-one
3(2H)-Pyridazinone, 4-hydroxy-6-[2-[4-(trifluoromethyl)phenyl]ethyl]- | [Molecular Formula]
C13H11F3N2O2 | [MDL Number]
MFCD34578240 | [MOL File]
1425511-32-5.mol | [Molecular Weight]
284.23 |
| Hazard Information | Back Directory | [Uses]
Luvadaxistat (TAK-831) is an orally active, highly selective, potent D-amino acid oxidase (DAAO) inhibitor. Luvadaxistat inhibits oxidative deamination of D-serine via the human recombinant DAAO enzyme with an IC50 of 14 nM. Luvadaxistat significantly increases D-serine levels in the rodent brain, plasma, and cerebrospinal fluid. Luvadaxistat has the potential for schizophrenia research[1][2]. | [in vivo]
Luvadaxistat (TAK-831; 0.001-3 mg/kg/days; PO; 14 days) dose-dependently improves social behavior in the social interaction (SI) test in BALB/c animals with rodent models of negative symptoms of schizophrenia[1].
Acute dosing of Luvadaxistat (0.3, 1, 3 mg/kg; p.o.) significantly reverses a poly(I:C)-induced deficit social preference in male C57BL/6 poly(I:C)-treated mice[1].
Luvadaxistat (1, 3, 10 mg/kg; p.o. at 2, 6, 10, and 24 h) inhibits DAAO by increased rat cerebellar d-serine levels in a dose- and time-dependent manner with a maximal effect observed at a dose of 10 mg/kg at 10 h post-dose in male Wistar rats weighing 240-280 g[1].
| Animal Model: | Male BALB/c mice (aged 9-10 weeks)[1] | | Dosage: | 0.001, 0.003, 0.01, 0.03, 0.1, 0.3, 1, 3 mg/kg | | Administration: | PO; daily; 14 days | | Result: | Dose-dependently improved social behavior in the SI test in BALB/c animals when dosed chronically (0.01-3 mg/kg).
|
| [storage]
Store at -20°C | [References]
[1] Rosa Fradley, et al. Luvadaxistat: A Novel Potent and Selective D-Amino Acid Oxidase Inhibitor Improves Cognitive and Social Deficits in Rodent Models for Schizophrenia. DOI:10.1007/s11064-023-03956-2
[2] Wang H, Norton J, Xu L, DeMartinis N, Sen R, Shah A, Farmer J, Lynch D. Results of a randomized double-blind study evaluating luvadaxistat in adults with Friedreich ataxia. Ann Clin Transl Neurol. 2021 Jun;8(6):1343-1352. DOI:10.1002/acn3.51373 |
|
|